Food and Drug Administration regulatory policy generally and policy for approval of new oncology diagnostic technologies
Reimbursement for new oncology diagnostic technologies generally, including public and private payers
Duration: March 1, 2017
to
July 31, 2020
General Issues: Health Issues , Medicare/Medicaid , Copyright/Patent/Trademark
Spending: about $410,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2017: House of Representatives, U.S. Senate, Health & Human Services - Dept of (HHS), Executive Office of the President (EOP), Centers For Medicare and Medicaid Services (CMS)
Related Foreign Entities:
F. Hoffmann-La Roche AG (Basel , SUI); contribution to lobbying: $0; ownership 57%
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
Dan Renberg Member, Board of Directors, Ex-Im Bank; Leg. Director and Dep. Chief of Staff. Sen. Arlen Specter
Sonja Nesbit Deputy Staff Director, Subcommittee on Human Resources, Committee on Ways and Means; Professional Staff, Subcommittee on Human Resources, Committee on Ways and Means
Philip English U.S. Representative
Oliver Spurgeon III Legislative Correspondent, Rep. Hank Johnson (2009-2015); Staff Assistant, Rep. Hank Johnson (2007-2009)
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
3rd Quarter, 2020
Arent Fox LLP terminated an engagement in which they represented Foundation Medicine, Inc. on Oct. 17, 2020.
Original Filing: 301212360.xml
Lobbying Issues
Food and Drug Administration regulatory policy generally and policy for approval of new oncology diagnostic technologies
Reimbursement for new oncology diagnostic technologies generally, including public and private payers
2nd Quarter, 2020
In Q2, Arent Fox LLP lobbied for Foundation Medicine, Inc. , earning $30,000. The report was filed on July 19, 2020.
Original Filing: 301194119.xml
Lobbying Issues
Food and Drug Administration regulatory policy generally and policy for approval of new oncology diagnostic technologies
S. 1895 (Lower Health Care Costs Act), Section 401, regarding hospital billing practices
H.R. 2328 (REACH Act), Title IV, regarding hospital billing practices
Reimbursement for new oncology diagnostic technologies generally, including public and private payers
H.R. 6102 (VALID Act of 2020), all provisions
Lobbying Issues
Medicare program policy for regulatory approval and reimbursement for new oncology diagnostic technologies
Reimbursement for new oncology diagnostic technologies generally
1st Quarter, 2020
In Q1, Arent Fox LLP lobbied for Foundation Medicine, Inc. , earning $30,000. The report was filed on April 20, 2020.
Original Filing: 301179088.xml
Lobbying Issues
Food and Drug Administration regulatory policy generally and policy for approval of new oncology diagnostic technologies
S. 1895 (Lower Health Care Costs Act), Section 401, regarding hospital billing practices
H.R. 2328 (REACH Act), Title IV, regarding hospital billing practices
Reimbursement for new oncology diagnostic technologies generally, including public and private payers
H.R. 6102 (VALID Act of 2020), all provisions
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medicare program policy for regulatory approval and reimbursement for new oncology diagnostic technologies
Reimbursement for new oncology diagnostic technologies generally
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2019
In Q4, Arent Fox LLP lobbied for Foundation Medicine, Inc. , earning $30,000. The report was filed on Jan. 20, 2020.
Original Filing: 301123613.xml
Lobbying Issues
Food and Drug Administration regulatory policy generally and policy for approval of new oncology diagnostic technologies
Drug pricing reforms generally
S. 1895 (Lower Health Care Costs Act), Section 401, regarding hospital billing practices
H.R. 2328 (REACH Act), Title IV, regarding hospital billing practices
H.R. 3 (Elijah E. Cummings Lower Drug Costs Now Act), all provisions
Reimbursement for new oncology diagnostic technologies generally, including public and private payers
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medicare program policy for regulatory approval and reimbursement for new oncology diagnostic technologies
Reimbursement for new oncology diagnostic technologies generally
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2019
In Q3, Arent Fox LLP lobbied for Foundation Medicine, Inc. , earning $30,000. The report was filed on Oct. 20, 2019.
Original Filing: 301072587.xml
Lobbying Issues
Food and Drug Administration regulatory policy generally and policy for approval of new oncology diagnostic technologies
Drug pricing reforms generally
S. 1895 (Lower Health Care Costs Act), Section 401, regarding hospital billing practices
H.R. 2328 (REACH Act), Title IV, regarding hospital billing practices
Lobbying Issues
Medicare program policy for regulatory approval and reimbursement for new oncology diagnostic technologies
Reimbursement for new oncology diagnostic technologies generally
2nd Quarter, 2019
In Q2, Arent Fox LLP lobbied for Foundation Medicine, Inc. , earning $30,000. The report was filed on July 20, 2019.
Original Filing: 301053197.xml
Lobbying Issues
Food and Drug Administration regulatory policy generally and policy for approval of new oncology diagnostic technologies
Drug pricing reforms generally
S.1895 (Lower Health Care Costs Act), Section 401, regarding hospital billing practices
Lobbying Issues
Medicare program policy for regulatory approval and reimbursement for new oncology diagnostic technologies
Reimbursement for new oncology diagnostic technologies generally
Lobbying Issues
Legislation regarding patent eligibility generally
Type of Issue
Copyright/Patent/Trademark
1st Quarter, 2019
In Q1, Arent Fox LLP lobbied for Foundation Medicine, Inc. , earning $30,000. The report was filed on April 20, 2019.
Original Filing: 301032463.xml
Lobbying Issues
Food and Drug Administration regulatory policy generally and policy for approval of new oncology diagnostic technologies
Drug pricing reforms generally
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medicare program policy for regulatory approval and reimbursement for new oncology diagnostic technologies
Reimbursement for new oncology diagnostic technologies generally
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2018
In Q4, Arent Fox LLP lobbied for Foundation Medicine, Inc. , earning $30,000. The report was filed on Jan. 19, 2019.
Original Filing: 301010963.xml
Lobbying Issues
Food and Drug Administration regulatory policy generally and policy for approval of new oncology diagnostic technologies
Drug pricing reforms generally
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medicare program policy for regulatory approval and reimbursement for new oncology diagnostic technologies
Reimbursement for new oncology diagnostic technologies generally
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2018
In Q3, Arent Fox LLP lobbied for Foundation Medicine, Inc. , earning $30,000. The report was filed on Oct. 20, 2018.
Original Filing: 300993572.xml
Lobbying Issues
Food and Drug Administration regulatory policy generally and policy for approval of new oncology diagnostic technologies
Drug pricing reforms generally
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medicare program policy for regulatory approval and reimbursement for new oncology diagnostic technologies
Reimbursement for new oncology diagnostic technologies generally
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2018
In Q2, Arent Fox LLP lobbied for Foundation Medicine, Inc. , earning $30,000. The report was filed on July 20, 2018.
Original Filing: 300978046.xml
Lobbying Issues
Food and Drug Administration regulatory policy generally and policy for approval of new oncology diagnostic technologies
Drug pricing reforms generally
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medicare program policy for regulatory approval and reimbursement for new oncology diagnostic technologies
Implementation of Protecting Access to Medicare Act regarding reimbursement for clinical laboratory services
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2018
In Q1, Arent Fox LLP lobbied for Foundation Medicine, Inc. , earning $30,000. The report was filed on April 20, 2018.
Original Filing: 300952613.xml
Lobbying Issues
Food and Drug Administration regulatory policy generally and policy for approval of new oncology diagnostic technologies
H.R. 1625 (Consolidated Appropriations Act, 2018), Division H--Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2018, regarding National Institutes of Health funding level
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medicare program policy for regulatory approval and reimbursement for new oncology diagnostic technologies
Implementation of Protecting Access to Medicare Act regarding reimbursement for clinical laboratory services
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2017
In Q4, Arent Fox LLP lobbied for Foundation Medicine, Inc. , earning $40,000. The report was filed on Jan. 20, 2018.
Original Filing: 300931741.xml
Lobbying Issues
Food and Drug Administration regulatory policy generally and policy for approval of new oncology diagnostic technologies
H.R. 3358 and S. 1771 (Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2018), regarding National Institutes of Health funding level
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medicare program policy for regulatory approval and reimbursement for new oncology diagnostic technologies
"14 Day Rule" regarding billing for clinical laboratory services
Implementation of Protecting Access to Medicare Act regarding reimbursement for clinical laboratory services
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2017
In Q3, Arent Fox LLP lobbied for Foundation Medicine, Inc. , earning $30,000. The report was filed on Oct. 20, 2017.
Original Filing: 300916765.xml
Lobbying Issues
Food and Drug Administration regulatory policy generally
S. 456 (RACE for Children Act), all provisions
H.R. 2430 (FDA Reauthorization Act of 2017), Title V, regarding RACE for Children Act and pediatric cancer treatment
H.R. 3358 and S. 1771 (Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2018), regarding National Institutes of Health funding level
H.R. 3354 (Make America Secure and Prosperous Appropriations Act, 2018), Division F -- Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2018, regarding National Institutes of Health funding level
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medicare program policy for regulatory approval and reimbursement for new oncology diagnostic technologies
"14 Day Rule" regarding billing for clinical laboratory services
Implementation of Protecting Access to Medicare Act regarding reimbursement for clinical laboratory services
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2017
In Q2, Arent Fox LLP lobbied for Foundation Medicine, Inc. , earning $20,000. The report was filed on July 20, 2017.
Original Filing: 300897516.xml
Lobbying Issues
FY' 18 Health and Human Services appropriations regarding Food and Drug Administration and National Institutes of Health
Food and Drug Administration regulatory policy generally
S. 456 (RACE for Children Act), all provisions
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medicare program policy for regulatory approval and reimbursement for new oncology diagnostic technologies
"14 Day Rule" regarding billing for clinical laboratory services
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2017
In Q1, Arent Fox LLP lobbied for Foundation Medicine, Inc. , earning $10,000. The report was filed on April 20, 2017.
Original Filing: 300873420.xml
Lobbying Issues
FY' 18 Health and Human Services appropriations regarding Food and Drug Administration and National Institutes of Health
Food and Drug Administration regulatory policy generally
Lobbying Issues
Medicare program policy for regulatory approval and reimbursement for new oncology diagnostic technologies
1st Quarter, 2017
Arent Fox LLP filed a lobbying registration on April 13, 2017 to represent Foundation Medicine, Inc., effective March 1, 2017.
Original Filing: 300865390.xml
Issue(s) they said they’d lobby about: Policies related to regulatory approval and reimbursment for new oncology diagnostic technologies .
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate
Searching...